FX-322 in Adults With Acquired Sensorineural Hearing Loss

Hearing Loss, Sensorineural Clinical Trial

Official title:

A Phase 2, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter Study to Evaluate the Efficacy of FX-322 Administered by Intratympanic Injection in Adults With Acquired Sensorineural Hearing Loss

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05086276
• Other study ID #: FX-322-208
• Status: Completed
• Phase: Phase 2
• Start date: October 12, 2021
• Est. completion date: December 30, 2022

Study information

• Verified date: April 2023
• Source: Frequency Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

Description:

This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter study to evaluate the efficacy of FX-322, administered by intratympanic injection, in adults with acquired sensorineural hearing loss (SNHL).

Previous human studies in subjects 18 to 65 years inclusive (FX-322-103, FX-322-201, FX-322-111) and subjects 66-85 inclusive (FX-322-112) demonstrated that a single dose FX-322 was well tolerated in patients with acquired SNHL with no treatment-related serious adverse events. Adverse events in these studies were generally common to and associated with the intratympanic injection procedure with mild and transient discomfort in patients both with the drug and the placebo.

Frequency Therapeutics' Investigators intend to evaluate efficacy with a single dose of FX-322 in subjects 18 to 65 years inclusive with acquired SNHL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 142
• Est. completion date: December 30, 2022
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Subject has read and voluntarily signed the Informed Consent Form (ICF) after all questions have been answered and prior to any study-mandated procedure.

2. Adult aged 18-65 years inclusive at Screening.

3. Documented medical history consistent with acquired, adult onset, sensorineural hearing loss associated with noise-induced SNHL (NIHL) or idiopathic sudden SNHL (SSNHL) (documented audiogram at least 6 months prior to screening required).

4. A pure tone average at the Screening Visit of 35-85 dB at 500Hz, 1000Hz, 2000Hz, and 4000Hz in the ear to be injected.

5. Ability to communicate well with the Investigator and is willing to comply with and complete all the study procedures.

6. Female subjects must be of non-childbearing potential or will need to utilize two methods of highly effective contraception during the study participation (e.g. hormonal contraception and condom or an intrauterine device and condom) or remain abstinent. Male subjects should use condoms with spermicide during the course of the study or remain abstinent. Subjects should not donate sperm or ova during the study period.

7. Have met additional masked criteria as determined by the Electronic Data Capture system.

Exclusion Criteria:

1. Subject has previously been randomized in a FX-322 clinical trial.

2. Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube.

3. Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10dB at two or more contiguous octave frequencies in the study ear at the Screening visit.

4. Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected.

5. Subject has had an intratympanic injection in either ear within 3 months of the screening visit.

6. Evidence of or previous diagnosis of auditory neuropathy, traumatic brain injury, "central" hearing loss, or genetic hearing loss.

7. History of chronic, recurrent clinically significant vestibular symptoms.

8. History of bilateral sudden sensorineural hearing loss or recurrent sudden sensorineural hearing loss.

9. History of clinically significant systemic autoimmune disease (e.g. rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, psoriasis).

10. History of head or neck radiation, treatment, or exposure to platinum based chemotherapy drugs or aminoglycosides.

11. Exposure to another investigational drug within 28 days prior to screening visit.

12. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator following a detailed medical history, physical examination, and vital signs (systolic and diastolic blood pressure, pulse rate, body temperature).

13. Positive urine pregnancy test or breast-feeding.

14. Any known factor, condition, or disease that, in the view of the Investigator, might interfere with treatment compliance, study conduct or interpretation of the results.

Related Conditions & MeSH terms

• Deafness
• Hearing Loss
• Hearing Loss, Noise-Induced
• Hearing Loss, Sensorineural
• Hearing Loss, Sudden
• Noise Induced Hearing Loss
• Sudden Hearing Loss

Intervention

Drug:
• FX-322
Active Comparator
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Clinical Trial Site	Albany	New York
United States	Clinical Trial Site	Amherst	New York
United States	Clinical Trial Site	Charleston	South Carolina
United States	Clinical Trial Site	Cincinnati	Ohio
United States	Clinical Trial Site	Colorado Springs	Colorado
United States	Clinical Trial Site	Dallas	Texas
United States	Clinical Trial Site	Fort Worth	Texas
United States	Clinical Trial Site	Fresno	California
United States	Clinical Trial Site	Marrero	Louisiana
United States	Clinical Trial Site	Milwaukee	Wisconsin
United States	Clinical Trial Site	Murray	Utah
United States	Clinical Trial Site	New York	New York
United States	Clinical Trial Site	Norfolk	Virginia
United States	Clinical Trial Site	Novi	Michigan
United States	Clinical Trial Site	Oklahoma City	Oklahoma
United States	Clinical Trial Site	Omaha	Nebraska
United States	Clinical Trial Site	Orangeburg	South Carolina
United States	Clinical Trial Site	Richmond	Virginia
United States	Clinical Trial Site	Saint George	Utah
United States	Clinical Trial Site	San Antonio	Texas
United States	Clinical Trial Site	Sarasota	Florida
United States	Clinical Trial Site	Spartanburg	South Carolina
United States	Clinical Trial Site	Tampa	Florida
United States	Clinical Trial Site	Torrance	California
United States	Clinical Trial Site	Tucson	Arizona
United States	Clinical Trial Site	Winston-Salem	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Frequency Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Word Recognition in Quiet	Percent of subjects exceeding the Carney-Schlauch 95% confidence interval for improvement from baseline in number of words recognized from Consonant-Nucleus-Consonant (CNC) word lists	Baseline through Day 90
Secondary	Words-in-Noise	Mean absolute percent change in number of recognized words from CNC word lists	Baseline through Day 90
Secondary	Standard Pure Tone Audiometry	Mean overall pure tone average (PTA) hearing thresholds in decibels (dB) derived by averaging the air conduction thresholds at 0.5, 1, 2 and 4 kHZ frequencies	Baseline through Day 90
Secondary	Patient Global Impression of Change (PGI-C) Hearing Loss Scale	Average response in PGI-C hearing loss scale, using the assigned numeric values of 1-5: 1) much better, 2) a little better, 3) no change, 4) a little worse 5) much worse	Day 90
Secondary	Patient Global Impression of Change (PGI-C) Daily Impacts Scale	Average response in PGI-C daily impacts scale, using the assigned numeric values of 1-5: 1) much better, 2) a little better, 3) no change, 4) a little worse 5) much worse	Day 90